A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

NCT02583542 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer
Squamous Cell Lung Cancer
Non-squamous Cell Lung Cancer With KRAS Mutations
Non-squamous Cell Lung Cancer With Wild-type KRAS

Interventions

DRUG: AZD2014
DRUG: AZD6244

Sponsor

Queen Mary University of London

Collaborators

[object Object]
[object Object]